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Highlights  
• Lead treatment induces curvature of the spine  
• We demonstrate changes in somites including decreased size, altered gene expression and 
altered muscle myofibrils 
• We demonstrate alterations in body vasculature and motor neuron development as well as 
increased apoptosis 
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Abstract   
Lead has been utilized throughout history and is widely distributed and mobilized globally.  
Although lead in the environment has been somewhat mitigated, the nature of lead and its 
extensive uses in the past prohibit it from being completely absent from our environment and 
exposure to lead is still a public health concern.  Most studies regarding lead toxicity have 
focused on the brain.  However, little is found in the literature on the effects of lead in other 
tissues.  Here, we utilize the zebrafish model system to investigate effects of lead exposure 
during early developmental time windows at 24, 48 and 72 hours post fertilization in the body.  
We analyze whole body, notochord and somatic muscle changes, vascular changes of the body, 
as well as motor neuron alterations.  We find lead exposure induces a curved body phenotype 
with concomitant changes in somite length, decreased notochord staining and abnormal muscle 
staining using live and in situ approaches.  Furthermore, altered vasculature within the somatic 
regions, loss and/or alternations of motor neuron extension both dorsally and ventrally from the 
spinal cord, loss of Rohon-Beard sensory neurons, and increased areas of apoptosis were found.  
We conclude that lead is developmentally toxic to other areas of the developing embryo, not just 
the brain.   
 
Keywords:  Zebrafish, Development, Lead, Vasculature, Notochord, Neurons 
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1.  Introduction  
Lead has been mined and used for over 6000 years, spiking during Roman times and the 
Industrial Revolution (Hernberg, 2000;  Philp, 2001).  During the past 100 years, lead was 
exclusively used in paints, canning, toy manufacturing, pesticides, lead shot, and as a gas 
additive (Philp, 2001;  Roy et al., 2014).  In the United States, use of lead in many products has 
been banned since the 1970’s, however, lead continues to contaminate our environment and is 
found in dust, street dirt, soil, water and food (Tong et al., 2000).  Current sources of lead 
exposure include past emissions of leaded gasoline accumulating in soil, abandoned industrial 
sites, smelting operations, older homes with leaded paint and lead pipes, as well as imported toys 
(Philp, 2001;  Tong et al., 2000).  Furthermore, a number of home hobbies can contribute to lead 
contamination including pottery and stained glass. Because lead was utilized globally and in such 
vast quantities, mitigating all the lead in our environment is impossible.  Chronic exposure to 
low levels of lead is a common health issue and acute lead poisoning can still occur, especially 
among socioeconomically disadvantaged groups and in developing countries lacking policies and 
environmental regulations (Tong et al., 2000).   
The zebrafish model has become particularly popular in the laboratory setting given its 
genetic and embryological similarities to higher order vertebrates including humans (Grunwald 
and Eisen, 2002).  Zebrafish share a high degree of homology with the human genome (Dai et 
al., 2014;  Howe et al., 2013) and thus, modeling of human diseases in zebrafish is now 
commonplace. From a toxicological perspective, zebrafish are particularly useful as their 
development is very well characterized (Hill et al., 2005;  Kimmel et al., 1995) and all stages of 
toxicological assessment can be made ex utero.   Of particular toxicological significance to the 
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model, they develop organs specific to toxin conversion, like the liver, very early in their 
development.  They also share the same liver metabolic pathways and cytochrome P450 (CYP) 
genes, most of which are direct orthologs of human CYPs (Goldstone et al., 2010;  Padilla et al., 
2012;  Tao and Peng, 2009).  Thus, the zebrafish can provide information that could not be 
gathered from other models and knowledge of the mechanisms of developmental toxicity is 
scarce (Teraoka et al., 2003).  Since the zebrafish genome has been sequenced, fluorescent 
transgenic zebrafish are relatively easy to construct and are visualized well in the optically 
transparent zebrafish embryo.  As zebrafish rapidly mature, transgenerational effects of toxin 
exposure can be assessed (Hill et al., 2005).  From an eco-toxicological perspective, zebrafish 
have been extensively used to study heavy metals, endocrine disrupting chemicals, and persistent 
organic pollutants (Dai et al., 2014).   
 Traditional approaches to toxicology include testing on common laboratory species like 
rat or rabbit, but this approach is time consuming and expensive.  Given the number of chemicals 
entering the market, the need for high throughput assays is significant.  The goal of the United 
States Environmental Protection Agency (EPA) ToxCastTM program is to develop cost-effective 
approaches to rapidly screen and prioritize chemicals that would require further toxicological 
testing.  High throughput testing has mainly involved in vitro assays and in silico modeling 
(Padilla et al., 2012).  However, in recent years, numerous labs have correlated zebrafish 
developmental toxicity with mammalian developmental toxicity validating the model (Busquet et 
al., 2008;  Padilla et al., 2012;  Selderslaghs et al., 2009) and thus, the EPA has recently launched 
a new toxicological initiative within the umbrella of the ToxCastTM program to utilize zebrafish 
developmental toxicity to model human health. Two approaches can be taken to study 
developmental toxicity: a low dose chronic exposure or a short high dose exposure.  The 
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ToxCastTM program utilizes the latter approach and treats embryos at early developmental time 
points with toxic chemicals at relatively high doses to investigate overt phenotypes and other 
organismal toxicity (Padilla et al., 2012) for predictive modeling of human developmental 
toxicity.  Although there is a wealth of knowledge on low dose chronic exposure to lead in 
children and its association with reduced IQ (Intelligence Quotient), ADHD (Attention Deficit 
Hyperactivity Disorder), and decreased cognitive abilities and hyperactivity (Lidsky and 
Schneider, 2003;  Needleman, 2004;  Philp, 2001;  Tong et al., 2000), there are few publications 
in the literature on short, high dose exposures.  Here, we have sought to model the EPA 
ToxCastTM approach to investigate a shorter high dose exposure and its effect on the developing 
body.  A high dose, short exposure of lead in zebrafish was investigated by Dou and Zhang, 
(2011), who found decreased gfap and huC gene expression in the diencephalon indicating 
neurogenesis was significantly compromised by lead during embryonic development (Dou and 
Zhang, 2011). However, they noted only slight changes in two other genes required for 
neurogenesis, ngn1 and crestin.  Neurogenin1 is expressed in the central nervous system (CNS), 
otic and epibranchial placodes and crestin in cranial and trunk neural crest cells.  However, their 
investigation on the effects of lead did not proceed past the 24hr time point  (Dou and Zhang, 
2011).  Springboarding off of their work and utilizing the same lead dose, we have also found 
structural abnormalities in the hindbrain including alterations in branchiomotor neuron 
development and migration.  Altered neural vasculature and increased neural apoptosis were also 
noted (Roy et al., 2014).  Here, we hypothesize that lead will also demonstrate developmental 
toxicity to other areas in addition to the brain and we investigate the effects of lead looking at 
live gross body phenotypes, notochord and muscle changes using an in situ and 
immunohistological approach and spinal neuron changes using a transgenic approach.  We find 
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lead exposure induces a curved body phenotype with concomitant changes in somite length, 
decreased notochord staining and altered muscle staining using live and in situ approaches.  
Additionally, altered vasculature within the somatic regions, loss and/or alterations of motor 
neurons extending dorsally and ventrally from the spinal cord, loss of Rohon-Beard sensory 
neurons, and increased areas of apoptosis were found.  We conclude that lead is developmentally 
toxic to other areas of the developing embryo, not just the brain.   
 
2.  Materials and Methods 
2.1 Zebrafish Breeding and Embryo Maintenance 
Adult zebrafish were housed in the Sacred Heart University Animal Facility in a standard 
zebrafish module (ZMOD (zebrafish module), Aquatic Habitats, Inc).  Adults were fed once 
daily with a combination of brine shrimp and supplemental TetraMin® Flake food.  A 10% 
water change was performed and water quality was monitored daily in accordance with IACUC 
(Institutional Animal Care and Use Committees) regulations.  Ammonia levels were kept below 
0.5ppm, nitrate levels below 80ppm, nitrite levels below 1ppm and the pH was kept between 6.5-
7.5.  The adults were maintained on a standard 14:10 hour light:dark wake to sleep cycle.  Two 
adult male and female pairs were placed in standard breeding boxes for mating purposes 
(Westerfield, 1993).  Embryos were collected the following morning and placed in 30% Danieau 
Buffer (Westerfield, 1993) prior to lead treatment.  Transgenic fli-1 gfp zebrafish were a 
generous gift from the Lawson Lab (University of Massachusetts Medical Center).  Transgenic 
neurogenin1 gfp and islet-1 gfp zebrafish were generous donations from the Linney Lab (Duke 
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University Medical Center).  All embryos were staged according to Kimmel (Kimmel et al., 
1995). 
2.2  Lead Acetate and Exposure Protocol 
Lead acetate was obtained from Sigma-Aldrich Chemical Company.  Solid lead powder was 
dissolved in 30% Danieau Buffer to a final concentration of 0.2mM.  Embryos were transferred 
to the control (30% Danieau Buffer) or lead solution (0.2mM) at 6 hour post fertilization (hpf) 
and treated continuously until 24, 48 and 72hpf when they were released from the lead treatment 
to control water.  As we wished to investigate the effect of lead on body development, treatments 
commenced at 6hpf to coincide with the onset of gastrulation.  After the treatment window ended 
(after 24, 48 or 72hpf), embryos were transferred to control water for safety purposes during 
imaging.  Treatments were performed in standard Petri dishes at 28.5º C as previously described 
(Roy et al., 2014).   Lead solution was changed daily and a maximum of 50 embryos were placed 
in each dish.  
2.3 Determination of Dose 
An LD50 was previously determined and the rationale for using the 0.2 mM dose was previously 
described (Roy et al., 2014).   Embryonic survivability at the dose was also previously described 
(Roy et al., 2014).  The 0.2 mM dose was also previously used to investigate the  effect of lead 
on swimming patterns and to assess larval escape responses (Dou and Zhang, 2011).   
2.4 Imaging and Microscopy (transgenic and non-transgenic embryos) 
Live images were obtained using a Leica dissection microscope attached to a Nikon Digital Sight 
DS-2Mv digital camera utilizing QCapture Software.  Transgenic green fluorescent images were 
obtained with a Nikon Eclipse E400 fluorescent microscope attached to a Retiga cooled CCD 
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(charge-coupled device) camera using QCapture Software.  Embryos were sedated in tricaine 
methanesulfonate (MS-222) (Westerfield, 1993) to inhibit movement during microscopy.  
Embryos were placed in a depression slide in 3% methylcellulose for positioning purposes (Roy 
et al., 2014).  In some cases (Figure 5, G,I and Figure 6, I), embryos were too curved to obtain 
in-focus whole body images and were hand manipulated into a straighter position with forceps in 
1% agar for imaging.   
2.5 Statistics 
The experiment was run as three independent trials.  For each trial, a total of 10 embryos in the 
control and lead treatment were imaged and measured at 24, 48 or 72hpf.  Thus, the total n for 
control and lead treatment at the three time points tested was 30.  Embryos were chosen at 
random from the treatment dishes.  Measurements of the somites were performed in Photoshop 
using the ruler function with pre-set measurements of length.  The PASW (Predictive Analytics 
Software) statistics program was utilized.  A Shapiro-Wilk normality test was performed prior 
conducting a 2-way ANOVA with factor of time (24, 48, 72hpf) and treatment (control or lead).   
A lead treatment p-value less than 0.05 is indicated with asterisks.   
2.6 Whole mount in situ hybridizations and immunohistochemistry 
Protocols for in situ hybridization were following according to Sagerström et. al (Sagerstrom et 
al., 1996).  The ntl probe was a generous gift from the Sagerström Lab (University of 
Massachusetts Medical Center, Worcester, MA).  The ntl probe was utilized as it is a common 
marker for the notochord (Schulte-Merker et al., 1994;  Yamada et al., 1991).  The probe was a 
Digoxigenin (DIG) labeled (Roche LifeScience, 11209256910) antisense RNA probe transcribed 
using the T7 in vitro transcription kit (Promega P1450).  The hybridized probes were visualized 
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in blue color using an anti-DIG antibody (Roche LifeScience, 11093274910) 
15016 -1 10001 AjaxOrderItemDis InvalidInputErrorV 12752
1 -1,-2,-3,-4,-5,-6,- 0 Y
true bound to nitroblue tetrazolium and bromo-4-chloro-indolyl phosphate 
(NBT/BCIP, Promega S3771).   
Whole mount immunohistochemistries were performed as previously described (Barresi 
et al., 2001;  Devoto et al., 1996).  An F59 antibody specific for myosin heavy chain was 
obtained from Developmental Studies Hybridoma Bank at the University of Iowa.  A 1:5 dilution 
of supernatant F59 antibody was utilized.  FITC-labeled goat anti-mouse secondary antibody 
(Santa Cruz Biotechnology) was utilized at a 1:200 dilution.  Embryos were imaged as described 
(Roy et al., 2014).   
2.7 Apoptotic Staining 
Embryos at 24, 48 and 72hpf were treated with Acridine Orange (Sigma-Aldrich Chemical 
Company, A6014).  A stock solution was prepared by dissolving 1mg of Acridine Orange 
powder into 1ml of distilled water.  Embryos were treated with a diluted stock in 30% Danieau 
Buffer at a concentration of 1µg/ml in Petri dishes for 1-2 hours in the dark.  After incubation, 
embryos were washed extensively in 30% Danieau Buffer and imaged under the fluorescent 
microscope using the FITC (Fluorescein Isothiocyanate) filter using sedation and imaging 
procedures are described above. 
 
3.  Results and Discussion 
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Lead is ubiquitous in our environment and exposure to and uptake of lead remains a 
serious health issue globally.  The neurotoxic effects of lead exposure in young children has been 
documented and linked to a number of behavioral abnormalities and learning disabilities (Dapul 
and Laraque, 2014;  Needleman, 2004).  However, most studies investigating lead focus on the 
brain and there is little in the literature on other toxic effects of lead to the developing embryo.  
In this study, we focused on development of the body including somitic development, 
vascularization of the body, motor neuron development and innervation of the somitic tissue 
during development in the presence of lead.   
3.1 Live body measurements 
To investigate if lead has other effects on the body beside the brain, we performed a time 
course of lead exposure and analyzed somite development.  Measuring the whole body along the 
straight A-P axis became problematic at the later time point (72hpf) due to spinal kyphosis.  
Furthermore, brain ventricle measurements and decreased ventricle lengths have already been 
noted (Roy et al., 2014).  Thus, we measured the length of six somites above the yolk sac 
extension for standardization.  More posterior somites near the tail are more constricted and 
smaller even in normal development.  Somites above the yolk sac extension have reached their 
consistent and reproducible size at each developmental time point and provide a means to 
compare lead treated embryos to controls.   
Live imaging of the development of embryos in lead solution at 24, 48 and 72hpf was 
performed to investigate changes in body and somite morphology.  No change in general gross 
morphology was seen between control and lead treatments at the 24hr and 48hr time points 
(Figure 1, A-H).  Somite boundaries in the body and the notochord were clearly defined (Figure 
1, B,D,F,H) and no body curving was seen.  However, by 48hpf, the lead treated embryos do 
Page 12 of 33
Ac
ce
pte
d M
an
us
cri
pt
12 
 
demonstrate slightly less optical clarity in the notochord and somites (Figure 1 H).   By the 72hr 
time point, curvature of the spine in lead treatments was seen (Figure 1, I,K) and somites became 
less clear compared to controls (Figure 1, J,L). Curvature of the spine with lead treatments has 
also been noted by others (Dou and Zhang, 2011).  The notochord also became less optically 
clear, although the structure was apparent.  To assess if lead had any effect on somatic growth, 
six somites running along the length of the yolk sac extension were measured.   The yolk sac 
extends during the segmentation stage during embryonic development and is well characterized 
and highly visible, providing a geographical landmark (Kimmel et al., 1995;  Virta and Cooper, 
2011).  A 2-way ANOVA detected a change in the length of the somites over time (p=<0.001) 
consistent with embryonic growth.  The 2-way ANOVA showed a significant effect of lead 
treatment in the somites (p=<0.001) and there was a significant interaction between time and 
lead treatment (p=<0.001).  It appears that lead had the greatest effect after 72hpf (Figure 2).  
Thus, somite length decreases due to lead exposure. 
3.2 In situ hybridization and immunohistochemistry 
As we detected decreased optical clarity in the notochord and somites at 48hpf, and 
evident changes in somite boundaries and optical clarity by 72hpf, we sought to investigate 
changes in these structures utilizing a common marker gene for the notochord, ntl (Schulte-
Merker et al., 1994;  Yamada et al., 1991) via in situ hybridization and a common muscle 
myofibril marker F59 via immunohistochemistry.  At 24hpf, ntl expression in control and lead 
treated embryos was apparent and strong along the length of the anterioposterior (A-P) body axis 
(Figure 3, A,B).  By 48hpf, ntl expression in lead treated embryos decreased with areas of 
stronger expression in the posterior spine and areas of weaker expression in the anterior spinal 
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region (Figure 3, C,D).  By 72hpf, ntl expression in lead treated embryos was weak throughout 
the A-P axis of the notochord (Figure 3, E,F) (Table 1).   
 At 24 and 48hpf, F59 antibody staining was apparent within the somites in the classic 
chevron shaped pattern and the linear myofibrils can clearly be seen (Figure 3, G-J).  By 72hpf, 
in lead treated embryos, the linear myofibril expression pattern in the chevron shape became 
altered (Figure 3, K-N).  The somite boundaries can be seen, although they are less linear and 
clear, as seen in live images in Figure 1, L.  Gaps in the myofibril pattern are seen.  In addition, 
the myofibrils lose the linear shape and become wavy and curved (Figure 3, L-N, Table 1).     
Interestingly zebrafish ntl mutants do not form a proper notochord, yet do form somites.  
However, these structures do not demonstrate the classic chevron shaped somite pattern (Halpern 
et al., 1993).  Our ntl defect is not a genetic mutation, so there was no complete loss of ntl from 
early embryonic stages.  It is interesting that we saw changes in F59 staining at 72hpf and only 
after the changes are noted in the notochord ntl staining at 48hr.   
3.3  Vascular Changes in somatic tissue 
To investigate if the somitic changes we noticed also resulted in changes in the 
vasculature pattern within the somitic tissue, we utilized the fli-1 gfp transgenic embryos.  The 
fli-1 promoter drives expression of green fluorescent protein in endothelial blood vessels during 
development (Lawson and Weinstein, 2002).  The signal was weak at 24hrs as the vasculature is 
developing, but by 48hpf, the GFP signal was strongly expressed in the intersegmental vessels 
(ISV) and the dorsal aorta.  Thus, only the 48 and 72hr time points were examined.   
No changes were seen at 48hpf in control or lead exposed embryos looking at gross 
vascularization or in magnified views of the somatic region (Figure 4 A-D).  The intersegmental 
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vessels (ISV) are well developed and extend up from the dorsal aorta (DA).  However, by 72hpf, 
noticeable changes in the vascularization became apparent (Figure 4, E-P).  A variety of vascular 
changes were noted, including incomplete ISVs (Figure 4, H-J), a lack of ISVs (Figure 4, K), 
abnormal branching patterns of ISVs (Figure 4, L-N), irregularly spaced ISVs (Figure 4, P) and 
irregularly shaped ISVs (Figure 4, O) (Table 2).  Many lead treated embryos demonstrated 
multiple ISV phenotypes within a single embryo (Table 2).   
There is a wealth of literature on blood lead levels as it relates to child health and 
development, but limited publications on physical alterations to the blood vessels themselves 
during development in response to lead.  Recently, Roy et al., (2014) investigated alterations in 
blood vasculature in the developing brain in response to lead and found alterations in the central 
artery of the hindbrain by 72hpf.  Vasculature at earlier stages appeared normal (Roy et al., 
2014).   This was consistent with results presented here in the body.  No changes in vasculature 
were seen prior to 72hpf.   
3.4  Neural changes in body 
In all vertebrate species, the notochord is required for neurectodermal patterning and 
signals formation of the floor plate of the neural tube.  Additionally, the notochord independently 
signals formation of motor neurons (Placzek et al., 1991;  Stemple et al., 1996;  van Straaten and 
Hekking, 1991;  Yamada et al., 1991).  Given the ntl phenotype we saw (Figure 3), we sought to 
investigate if lead would alter motor neuron development utilizing two transgenics, islet-1 gfp 
(Higashijima et al., 2000) and neurogenin1 gfp (Blader et al., 2003;  Fan et al., 2011).   
Control and lead treated islet-1 gfp embryos developed Rohon-Beard sensory neurons 
along the length of the anterioposterior (A-P) spine by 48hrs (Figure 5, A-D).  Dorsal projections 
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of the spinal motor neurons have not yet extended at 48hrs.  By 72hpf, control embryos 
demonstrated very strong Rohon-Beard neurons along the A-P axis of the spine and show strong 
dorsally projecting motor neurons (Figure 5, E,F).  Lead treated islet-1 gfp embryos showed a 
loss of Rohon-Beard neurons in the anterior spinal region, and weakened and/or jumbled Rohon-
Beard cell bodies in the posterior spine (Figure 5, G-J).  This is interesting as we also saw a loss 
of ntl expression in the anterior region of the notochord at 48hpf (Figure 3, D).  Furthermore, 
lead treated embryos showed a complete lack of dorsally projecting motor neurons or 
demonstrated incomplete or abnormal extension of motor neurons (Figure 5, H,J) (Table 3).   
The GFP signal in neurogenin1 transgenic embryos does not become strong until after 
48hpf and thus, only the 72hpf time point was assessed.  In control embryos, neurogenin1 was 
expressed strongly along the length of the entire neural tube (Figure 6 A,C).  Dorsal root 
ganglion (DRG) cells are clearly seen and evenly spaced along the length of the spinal cord 
(Figure 6, C, D) by 72hpf.  Spinal cord motor neurons have extended ventrally to innervate the 
body tissue (Figure 6, B).  By 72hpf, lead treated embryos demonstrated weakened, absent, or 
incomplete ventral motor neuron extension (Figure 6, E,F,I,J).  The evenly spaced pattern of the 
DRG along the spine became disorganized and unclear (Figure 6, G,H,K,L) (Table 3).  In some 
cases, it became difficult to define the DRG cell bodies.   
Studies have shown that ablation of the notochord prevents differentiation of spinal 
motoneurons (van Straaten and Hekking, 1991;  Yamada et al., 1991).  Although we did not 
ablate the notochord, we did detect changes in ntl expression in response to lead, suggesting 
alteration to the notochord structure.  This could then alter signals being sent to the neural tube 
and the signals being sent for development of the spinal motoneurons.  This seems consistent 
with our results in the islet-1 and neurogenin1 transgenic embryos.  It is interesting however, that 
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the neurogenin1 phenotype is consistent along the A-P axis whereas the islet-1 phenotype 
appears prominently along the anterior spinal region.  Previously, neurogenin1 (ngn1) in situ 
hybridizations have been performed, but only slight changes in ngn1 expression were found 
(Dou and Zhang, 2011).  However, the only time point assessed in the study was 24hrs.  As our 
transgenic does not produce a strong signal until 72hrs, the earlier time points could not be 
assessed.   
The results seen in regards to motor neurons are interesting and could be correlated with 
the behavioral and swimming deficits previously noted in the literature.  We detected alterations 
to the Rohon-Beard sensory neurons in the islet-1 transgenic fish as well as abnormally patterned 
dorsal root ganglion sensory neurons in the neurogenin1 transgenic embryos in lead treatments.  
Furthermore, we detected alterations and/or loss of the dorsally and ventrally extending motor 
neurons.   The changes we detected could be related to known behavioral defects seen in 
zebrafish including decreases in startle response (Rice et al., 2011), swimming patterns and 
speeds (Chen et al., 2012;  Rice et al., 2011) and escape reactions (Dou and Zhang, 2011).   
3.5  Increased Apoptosis 
Lastly, we also investigated if lead treatment caused an increase in apoptosis in the body.  
Others have noted increased apoptosis in response to lead in the brain (Dou and Zhang, 2011;  
Peterson et al., 2013;  Roy et al., 2014), but we also wanted to investigate if the body 
demonstrated increased levels of apoptosis as well.  Control and lead exposed embryos were 
treated with Acridine Orange live dye staining to detect apoptotic cells at 24, 48 and 72hpf.  At 
24hr and 48hrs, no gross detectable apoptotic cells were detected in control or lead treated 
embryos (Figure 7, A-D).  At 24hpf, it is common to see some sporadic spots as the embryo has 
just undergone numerous normal patterning processes including programmed cell death (Figure 
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7, A,B).  By 72hpf apoptotic cell clusters became apparent within the somatic tissue (Figure 7, E-
H).  Some apoptotic cells were sporadic (Figure 7, F) but mainly apoptosis was found in clusters 
in the notochord and the somites (Figure 7, G,H).  Interestingly, the clusters did not necessarily 
overlap with regions where we noted changes, for example, the anterior spinal regions where 
islet-1 motor neurons were lost.  This apoptosis could reflect general toxicity of lead at the later 
time point.  The thickness of the body tissue and the limitations of a non-confocal microscope 
permit only a qualitative assessment of apoptosis.   
4.  Conclusion   
 Here, we utilized the well-established zebrafish model of vertebrate developmental 
toxicity to investigate the effects of lead exposure on the developing body.  We provide evidence 
that lead causes alterations to the notochord and somite morphology using live and in situ 
approaches.  Furthermore, we demonstrate lead causes alteration to the body vasculature, 
changes in Rohon-Beard and dorsal root ganglion sensory neurons, and defects in extension of 
dorsal and ventrally projecting motor neurons.  Increased apoptotic clusters were also noted.  
These results are interesting and preliminary and in no way demonstrate a mechanism, but a 
potential interesting connection between early effects of lead on the developing notochord and 
later staged motor neuron development could be postulated.  Future experiments would involve a 
more comprehensive study of the notochord during lead exposure utilizing other notochord 
markers like floating head (flh), momo (mom) and doc required for early notochord development 
(Odenthal et al., 1996).  Additionally, since alterations of ntl expression has been shown to alter 
somatic development, a more comprehensive study of muscle development could be performed 
looking at other muscle markers like myf5 and myogenin (Weinberg et al., 1996) as well as 
specific antibody stains to assess changes on fast and slow muscle subtypes.  Clearly, much still 
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remains to be investigated on the developmental toxicity of lead, but here we show lead is 
developmentally toxic to other aspects of the embryo, not just the brain.   
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Figure 1:  Live images of control and lead treated embryos. (A-D), 24hpf, (E-H), 48hpf, (I-L), 
72hpf.  Control (A,B,E,F,I,J) and lead treated (C,D,G,H,K,L).  All images are lateral views, 
anterior to left.  Images are shown in full view (A,C,E,G,I,K) next to magnified view of the 
somatic tissue (B,D,F,H,J,L).  Dashed lines represent somite boundaries.  Double arrow 
represents the notochord width.  Arrows (L) represent altered and unclear somatic boundaries.  
YSE:  Yolk sac extension.   
Figure 2:  Somite measurements at 24, 48 and 72hpf.  Measurements are in millimeters.  Each 
value represents means +/- standard deviations of a total of 30 embryos (three independent 
experiments with an n of 10 each for control and lead were performed).  Asterisk denotes lead 
treatment value of less than 0.05.   
Figure 3:  In situ hybridization and immunohistochemistry at 24, 48 and 72hpf.  (A,B,G,H) 
24hpf, (C,D,I,J) 48hpf, (E,F,K-N) 72hpf.  Control (A,C,E,G,I,K) and lead treated 
(B,D,F,H,J,L,M,N).  All images are lateral views, anterior to left.  (A-F) ntl in situ staining with 
magnified inset, (G-N) F59 antibody staining.  Dashed lines represent somite boundaries.  
Arrows denote gaps in the myofibril pattern within the somite and arrowheads denote non-linear 
wavy myofibrils.   
Table 1:  Total number of embryos in control and lead treatments demonstrating wild-type and 
aberrant phenotypes for ntl in situ hybridization and F59 antibody staining at 24, 48 and 72hpf.  
Numbers are shown as fractions and percentages.  A total of 30 embryos per treatment were 
tested (three independent experiments with an n of 10 each for control and lead were performed).   
Figure 4:  Somitic vasculature visualized with fli-1 gfp transgenics.  (A-D) 48hpf, (E-P) 72hpf.  
Control (A,B,E,F) and lead treated (C,D,G-P).  All images are lateral views, anterior to left.  
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Images are shown in full view (A,C,E,G) or in magnified views to illustrate vascular changes 
(B,D,F,H-P) shown by arrows.  ISV:  intersegmental vesicle, DA:  dorsal aorta.  
Table 2:  Total number of embryos in control and lead treatments demonstrating aberrant 
phenotypes at 48 and 72hpf in fli-1 gfp transgenic embryos.  Numbers are shown as fractions and 
percentages.  A total of 30 embryos per treatment were tested (three independent experiments 
with an n of 10 each for control and lead were performed).   
Figure 5:  Neuron development in the body utilizing islet-1 gfp transgenic embryos.  (A-D) 
48hpf, (E-J) 72hpf.  (A,B,E,F) control and (C,D,G-J) lead treated.  All images are lateral views, 
anterior to left.  Images are shown in full view (A,C,E,G,I) next to magnified view of the somatic 
tissue (B,D,F,H,J).  Dashed lines represent somite boundaries.  RB:  Rohon-Beard neurons, 
arrowheads denote dorsal extension of motor neurons from spinal cord.   
Figure 6:  Neuron development in the body utilizing neurogenin1 gfp transgenic embryos. (A-L) 
72hpf.  (A-D) control and (E-L) lead treated.  (A,B,E,F,I,J) lateral views, anterior to left, 
(C,D,G,H,K,L) dorsal views, anterior to left.  Images are shown in full view (A,C,E,G,I,K) next 
to magnified view of the somatic tissue (B,D,F,H,J,L).  DRG:  Dorsal root ganglion, arrowheads 
denote ventral extension of motor neurons from spinal cord, asterisks denotes incomplete or 
missing motor neuron extension.   
Table 3:  Total number of embryos in control and lead treatments demonstrating aberrant 
phenotypes at 48 and 72hpf for islet-1 gfp and neurogenin1 gfp transgenics.  Numbers are shown 
as fractions and percentages.  A total of 30 embryos per treatment were tested (three independent 
experiments with an n of 10 each for control and lead were performed).   
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Figure 7:  Apoptosis in the somatic tissue.  (A,B) 24hpf, (C,D) 48hpf, (E-H) 72hpf.  (A,C,E) 
control and (B,D,F-H) lead treated in lateral views.  Control somitic tissue demonstrated few 
apoptotic spots (A,C,E) at 24,48 or 72hpf.  Lead treated embryos showed few apoptotic spots at 
24 or 48hpf (B,D), but demonstrate increased numbers of apoptotic cells (F) or large apoptotic 
cellular clusters (G,H) by 72hpf.  Dashed lines outline somatic boundaries, arrows note apoptotic 
clusters. 
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Time Treatment 
Normal 
expression along 
A-P axis 
Weakened 
anterior spine 
expression 
Overall weakened 
expression along 
A-P axis 
Control 30/30  (100%) 
0/30  
(0%) 
0/30  
(0%) 
24hr 
Lead 30/30  (100%) 
0/30  
(0%) 
0/30  
(0%) 
Control 29/30  (96.6%) 
1/30  
(3.3%) 
0/30  
(0%) 
48hr 
Lead 5/30 (16.6%) 
25/30  
(83.3%) 
0/30  
(0%) 
Control 30/30  (100%) 
0/30  
(0%) 
0/30  
(0%) 
72hr 
Lead 0/30  (0%) 
12/30 
(40%) 
18/30 
(60%) 
  n=10 per experiment, replicate=3 
  
F59 Antibody 
Time Treatment 
Normal chevron 
shaped 
expression 
within somite 
Gaps within 
myofibrils  
Non-linear 
myofibrils  
(curvy myofibrils) 
Control 30/30  (100%) 
0/30  
(0%) 
0/30  
(0%) 
24hr 
Lead 30/30  (100%) 
0/30  
(0%) 
0/30  
(0%) 
Control 30/30  (100%) 
0/30  
(0%) 
0/30  
(0%) 
48hr 
Lead 27/30 (90%) 
1/30  
(3.3%) 
0/30  
(0%) 
Control 30/30  (100%) 
0/30  
(0%) 
0/30  
(0%) 
72hr 
Lead 6/30  (20%) 
22/30 
(73.3%) 
26/30 
(86.7%) 
  n=10 per experiment, replicate=3 
Table 1 
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fli-1 
Time Treatment lack of ISV 
incomplete 
ISV 
branching 
of  ISV 
irregular 
spacing of 
ISV 
irregular 
shaped 
ISV 
Control 0/30  (0%) 
1/30  
(3.3%) 
2/30 
(6.7%) 
0/30  
(0%) 
1/30 
(3.3%) 
48hr 
Lead 0/30 (0%) 
2/30  
(6.6%) 
3/30  
(10%) 
0/30 
(0%) 
2/30 
(6.6%) 
Control 0/30  (0%) 
2/30 
(6.7%) 
2/30 
(6.7%) 
0/30 
(0%) 
2/30 
(6.7%) 
72hr 
Lead 10/30 (33.3%) 
19/30 
(63.3%) 
17/30 
(56.7%) 
23/30 
(76.7%) 
21/30 
(70%) 
  n=10 per experiment, replicate=3 
 
Table 2 
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islet-1gfp 
Time Treatment 
lack of motor 
neuron dorsal 
extension 
incomplete/abnormal 
extension of motor 
neuron dorsal 
extension 
Rohon-Beard cells  
fully present along 
A-P axis 
Rohon-Beard cells  
incomplete along A-
P axis 
Control 30/30  (100%) 
0/30  
(0%) 
28/30 
(93.3%) 
2/30  
(6.6%) 
48hr 
Lead 30/30 (100%) 
0/30  
(0%) 
27/30  
(90%) 
3/30 
(10%) 
Control 0/30  (0%) 
0/30 
(0%) 
30/30 
(100%) 
0/30 
(0%) 
72hr 
Lead 12/30 (40%) 
18/30 
(60%) 
3/30 
(10%) 
27/30 
(90%) 
  n=10 per experiment, replicate=3 
            
neurogenin1 gfp 
Time Treatment 
lack of motor 
neuron ventral 
extension 
incomplete/abnormal 
extension of motor 
neuron ventral 
extension 
Dorsal root 
ganglion cells  fully 
present and evenly 
spaced along A-P 
axis 
Dorsal root 
ganglion cells  
absent/altered along 
A-P axis 
Control 0/30  (0%) 
0/30 
(0%) 
30/30 
(100%) 
0/30 
(0%) 
72hr 
Lead 2/30 (6.6%) 
28/30 
(93.3%) 
3/30 
(10%) 
27/30 
(90%) 
  n=10 per experiment, replicate=3 
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